GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioverativ Inc (NAS:BIVV) » Definitions » Asset Turnover

Bioverativ (Bioverativ) Asset Turnover : 0.21 (As of Dec. 2017)


View and export this data going back to 2017. Start your Free Trial

What is Bioverativ Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Bioverativ's Revenue for the three months ended in Dec. 2017 was $329 Mil. Bioverativ's Total Assets for the quarter that ended in Dec. 2017 was $1,536 Mil. Therefore, Bioverativ's Asset Turnover for the quarter that ended in Dec. 2017 was 0.21.

Asset Turnover is linked to ROE % through Du Pont Formula. Bioverativ's annualized ROE % for the quarter that ended in Dec. 2017 was 68.60%. It is also linked to ROA % through Du Pont Formula. Bioverativ's annualized ROA % for the quarter that ended in Dec. 2017 was 36.80%.


Bioverativ Asset Turnover Historical Data

The historical data trend for Bioverativ's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioverativ Asset Turnover Chart

Bioverativ Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17
Asset Turnover
- 0.36 1.32 1.47 0.99

Bioverativ Quarterly Data
Dec13 Dec14 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.34 0.27 0.21 0.21

Competitive Comparison of Bioverativ's Asset Turnover

For the Biotechnology subindustry, Bioverativ's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioverativ's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioverativ's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Bioverativ's Asset Turnover falls into.



Bioverativ Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Bioverativ's Asset Turnover for the fiscal year that ended in Dec. 2017 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2017 )/( (Total Assets (A: Dec. 2016 )+Total Assets (A: Dec. 2017 ))/ count )
=1168.5/( (731.9+1618.3)/ 2 )
=1168.5/1175.1
=0.99

Bioverativ's Asset Turnover for the quarter that ended in Dec. 2017 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2017 )/( (Total Assets (Q: Sep. 2017 )+Total Assets (Q: Dec. 2017 ))/ count )
=328.7/( (1453.5+1618.3)/ 2 )
=328.7/1535.9
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Bioverativ  (NAS:BIVV) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Bioverativ's annulized ROE % for the quarter that ended in Dec. 2017 is

ROE %**(Q: Dec. 2017 )
=Net Income/Total Stockholders Equity
=565.2/823.95
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(565.2 / 1314.8)*(1314.8 / 1535.9)*(1535.9/ 823.95)
=Net Margin %*Asset Turnover*Equity Multiplier
=42.99 %*0.856*1.8641
=ROA %*Equity Multiplier
=36.80 %*1.8641
=68.60 %

Note: The Net Income data used here is four times the quarterly (Dec. 2017) net income data. The Revenue data used here is four times the quarterly (Dec. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Bioverativ's annulized ROA % for the quarter that ended in Dec. 2017 is

ROA %(Q: Dec. 2017 )
=Net Income/Total Assets
=565.2/1535.9
=(Net Income / Revenue)*(Revenue / Total Assets)
=(565.2 / 1314.8)*(1314.8 / 1535.9)
=Net Margin %*Asset Turnover
=42.99 %*0.856
=36.80 %

Note: The Net Income data used here is four times the quarterly (Dec. 2017) net income data. The Revenue data used here is four times the quarterly (Dec. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Bioverativ Asset Turnover Related Terms

Thank you for viewing the detailed overview of Bioverativ's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioverativ (Bioverativ) Business Description

Traded in Other Exchanges
N/A
Address
Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Brian S Posner director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Cox director, officer: Chief Executive Officer C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
John Greene officer: EVP, CFO and Treasurer 51 LIME STREET, LONDON X0 EC3M 7DQ
Geno J Germano director 5 GIRALDA FARMS, MADISON NJ 07940
Louis J Paglia director C/O UIL HOLDINGS CORP, 157 CHURCH STREET, NEW HAVEN CT 06506
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Diantha Duvall officer: Chief Accounting Officer C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Vivaldi Coelho Rogerio officer: EVP, Chief Global Therapeutics 225 SECOND AVENUE, WALTHAM MA 02451
Harris Timothy J.r. officer: EVP, R & D C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451
Lucia Celona officer: EVP, HR & Corp Commun. Officer BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Richard Brudnick officer: EVP, Business Development BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142

Bioverativ (Bioverativ) Headlines

From GuruFocus

Seeking Value in Biotech: Bioverativ

By Mark Yu Mark Yu 06-29-2017

Jeff Ubben Buys 1, Sells 1 in 1st Quarter

By Sydnee Gatewood Sydnee Gatewood 05-24-2017

5 Companies Hit 52-Week Highs

By yifan900 yifan900 05-29-2018